Mavelertinib (PF-06747775) (67) is an orally available and irreversible EGFR TKI that selectively targets various EGFR mutants, such as Del, L858R, T790M/L858R and T790M/Del, with less than 50% effect or inhibition against all nonkinase targets.196–198 In May 2015, a clinical study (NCT02349633) was initiated to investigate mavelertinib in patients with NSCLC EGFR mutation (Del 19 or L858R +/− T790M). Here, EGFR is linked to non-small cell lung carcinoma.